Frontlight ResearchEarly access
CompletedNo phase
HCV Microfluidic Diagnostics
Key facts
- Who runs it
- University of Hull
- Where
- United Kingdom1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 38 people enrolled
- Started
- 1 May 2023
- Ended
- 31 Mar 2024
- Type of study
- Observational, 2 groups
- Record updated
- 10 July 2024
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- Blood sample taken
Who cannot take part
- None
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Hepatitis C diagnostic devices have been developed at the University of Hull to detect and quantify the Hepatitis C virus in patients' plasma and serum samples. This study aims to test the new point-of-care devices that are designed to be low cost and user-friendly.
Read full original descriptionShow less
Excess, stored, HCV patients' plasma, serum and blood samples will be supplied by the Virology laboratory (Hull University Teaching Hospital's Trust; HUTH). These samples were taken and analysed as part of patients' clinical monitoring, and are stored prior to disposal in the Virology laboratory. The proposed study will use the samples in a fully anonymised manner.
The 2 groups in the trial
- Test
Hep C positive
- Control
Hep C negative
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Development of Point-of-care and Wearable Sensors for Hepatitis C Diagnostics
- Record updated
- 10 July 2024